Showing results (1-10 of 36) with videos related to
Sort By:
Pageof 4
Therapie|December 13, 2021
The challenge of targets and drug discovery using large-scale screening approaches in onco-hematologyLina Benajiba, Jean-Jacques KiladjianBlood|October 30, 2024
Current myeloproliferative neoplasm scoring systems for clinical practiceHélène Pasquer, Jean-Jacques Kiladjian, Lina BenajibaOncogenesis|May 7, 2026
Metabolic modulation of immune cell function: mechanisms and therapeutic implications in cancer immunotherapyNina Fenouille, Camille Lobry, Lina Benajiba, et al.Journal of Medicinal Chemistry|October 27, 2015
Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid LeukemiaTheresa Neumann, Lina Benajiba, Stefan Göring, et al.Cancers|March 6, 2021
Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a CureHélène Pasquer, Maëlys Tostain, Nina Kaci, et al.Leukemia|March 31, 2023
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscapeNabih Maslah, Lina Benajiba, Stephane Giraudier, et al.Therapie|August 27, 2022
Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses' infectionsZineb Ghrieb, Maud Salmona, David Michonneau, et al.Cancers|June 2, 2021
Systemic Treatment Initiation in Classical and Endemic Kaposi's Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort StudyLina Benajiba, Jérôme Lambert, Roberta La Selva, et al.Human Molecular Genetics|November 5, 2010
Rare melanocortin-3 receptor mutations with in vitro functional consequences are associated with human obesityMonica Mencarelli, Beatrice Dubern, Rohia Alili, et al.Anti-Cancer Drugs|February 23, 2017
Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring systemLina Benajiba, Jean-Marie Michot, Capucine Baldini, et al.Pageof 4